Friday’s analyst upgrades and downgrades

TD Securities upgraded Power Corp. to buy and kept a C$74 target after Q4 adjusted EPS of C$1.36 (vs C$1.44 consensus); the stock trades at a 23.5% discount to NAV, 10.5x P/E, and management plans ~1.9% buybacks (~$840mm) in 2026 and a 9% dividend raise. Premium Brands reported 4Q adjusted EBITDA of $180mm (vs $168mm consensus), yet shares fell 6.5%; guidance for 2026 revenue C$9.25–9.55b and EBITDA C$870–910m prompted mixed analyst reactions (targets C$108–C$120). MDA had its PT raised to C$53 on US IPO visibility and upside potential, while Sylogist was downgraded to neutral with Q4 revenue $14.4m and EBITDA $1.0m missing Street estimates, highlighting execution and margin risks.

Analysis

Power Corp’s management leaning into parent-level buybacks plus a defensive large-cap profile creates a classic arbitrage/re-rating setup for patient capital. Reduced free float across the group (if subsidiaries also repurchase) and steady dividend policy make the stock sensitive to shifts in income-seeking allocations — a modest inflow can move the discount to NAV materially in 6–12 months. The main near-term risk is that operational hiccups at core operating companies or a macro-driven hit to dividend growth would widen the discount again; monitor subsidiary buyback cadence and cash deployment statements as leading indicators.

Premium Brands’ ability to pass through input cost inflation via contractual or pricing levers is the key variable — if effective, EBITDA resilience should outpace peers and justify multiple expansion when leverage falls. Conversely, prolonged high protein costs or weakening foodservice demand would force more aggressive price or channel shifts, compressing margins and slowing deleveraging; asset sales can accelerate balance-sheet repair but may shave future growth, so track announced divestitures and leverage metrics on a quarterly cadence. Watch club/private-label channel dynamics as an early signal of consumer trade-downs.

MDA’s US listing dynamic removes a distribution friction and could catalyze multiple re-rating if it secures non-domestic constellation wins; the pairing of higher liquidity and sector IPO momentum is a technical tailwind. Sylogist remains a classic execution-risk story: near-term margin pain from transition can persist even if long-term ARR economics are attractive, making it a binary quarter-to-quarter trading name until NRR and bookings stabilize.

Key Decisions for Investors

• POW.TO — Buy a core position (6–12 month horizon). Size 3–5% NAV, or 60% of intended exposure long stock + sell 9–12 month lightly OTM calls to harvest yield while waiting for discount compression. Risk: parent/subsidiary operational slip widens NAV discount; set a tactical stop at a 12–15% drawdown from entry or trim into any quick 15%+ rally.
• PBH.TO — Accumulate on pullbacks into multi-quarter value/restructuring trade (12–24 months). Size 2–4% NAV; add on confirmed asset-sale announcement or measurable reduction in net leverage (0.2–0.4x improvement). Risk/reward: asymmetric if divestitures accelerate deleveraging versus downside if input-cost passthrough fails — use tight stops or pair against a consumer staples ETF to hedge cost-driven downside.
• MDA.TO — Buy LEAPs or buy stock before expected US re-listing to capture liquidity-driven multiple expansion (12–24 months). Use 1–2% NAV in options or 2–3% in stock. Catalyst: non-Canadian constellation awards and successful US offering; tail risk: IPO delays or contract slippage.
• SYZ.TO — Short or buy puts tactically (3–9 months) to play continued execution risk, keeping position small (<=1–2% NAV) due to binary recovery potential. Close or flip to long if quarterly releases show stabilized bookings/NRR and improving gross margins.